Zydus Receives USFDA Approval For ZITUVIMET To Treat Adult Patients With Type 2 Diabetes Mellitus

Zydus Receives USFDA Approval For ZITUVIMET To Treat Adult Patients With Type 2 Diabetes Mellitus

The shares of Zydus Lifesciences Limited on Monday at 9:47 am IST were trading at Rs 587.25, up by 0.41 percent.

FPJ Web DeskUpdated: Monday, November 06, 2023, 09:50 AM IST
article-image
Zydus Receives USFDA Approval For ZITUVIMET To Treat Adult Patients With Type 2 Diabetes Mellitus | Image: Zydus (Representative)

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as Zydus) on Monday announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for ZITUVIMETTM (Sitagliptin and Metformin hydrochloride) tablets, 50 mg/500 mg and 50 mg/1000 mg, the company announced through an exchange filing.

ZITUVIMET contains active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The approval of ZITUVIMET is based on research, development, regulatory, and manufacturing work performed by Zydus teams. ZITUVIMET has undergone quality testing for Nitrosamines and potential genotoxic impurities as per current USFDA standards. ZITUVIMETTM is compliant with current USFDA standards of Nitrosamines in Sitagliptin containing products.

“The ZITUVIMET approval further builds on our previous approval of ZITUVIOTM (Sitagliptin) and offers an increased accessibility and affordability to healthcare systems with regard to prescription drugs for type II diabetes. The ZITUVIMETTM approval provides an affordable treatment option for healthcare systems to reduce the rate of growth in drug spending and improves the financial sustainability of the healthcare programs,” said Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited.

According to IQVIA™ (MAT Aug-2023), U.S. market for DPP-IV inhibitors and their combinations is US$ 10 bn.

Zydus Lifesciences Limited shares

The shares of Zydus Lifesciences Limited on Monday at  9:47 am IST were trading at Rs 587.25, up by 0.41 percent.

RECENT STORIES

Amitabh Kant Joins IndiGo As Non-Executive Director 3 Weeks After Resigning As G20 Sherpa

Amitabh Kant Joins IndiGo As Non-Executive Director 3 Weeks After Resigning As G20 Sherpa

Flyers With Credit Cards Can Now Access Adani Airport Lounges Without Extra Registration

Flyers With Credit Cards Can Now Access Adani Airport Lounges Without Extra Registration

Gold Jumps ₹450 To ₹99,620/10 Grams; Silver Rallies ₹1,000

Gold Jumps ₹450 To ₹99,620/10 Grams; Silver Rallies ₹1,000

Tech Layoffs in 2025: Microsoft, Google, Intel, Infosys Reduce Workforce

Tech Layoffs in 2025: Microsoft, Google, Intel, Infosys Reduce Workforce

India May Be Subject To Lower US Tariffs Compared To APAC Nations: Moody's

India May Be Subject To Lower US Tariffs Compared To APAC Nations: Moody's